Jesduvroq Generic: When Will Generic Daprodustat Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Jesduvroq Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? December 2033 About 7 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? March 2038 6 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic daprodustat is expected to be available in December 2033, about 7 years away. None is for sale yet.
Why December 2033?
It is when Jesduvroq’s patent 8,324,208 ends. That patent covers the active ingredient and the product’s formulation, and once it ends, generics should be able to go on sale as soon as the FDA approves them. It is too early to rate how firm that is.
If Jesduvroq’s last patent runs to March 2038, how can a generic come sooner?
The 2 patents that run past the expected month, to March 2038 (11,117,871 and 11,649,217), cover the active ingredient, the product’s formulation and a way of using it. A generic can still come sooner if a court rules a patent invalid or not infringed, or if the companies settle on an earlier date. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Jesduvroq as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Jesduvroq by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Not rated Too early to rate. The month is where the records point today.
- Price competition
- None filed yet No filers on record
- Brand sales
- Sales not reported
- FDA approved 2023 February 2023 FDA Orange Book
- Patents listed 6 last runs to March 2038 A generic is expected sooner, in December 2033. See why FDA Orange Book
Jesduvroq’s Road to a Generic
Jesduvroq has had the market to itself since the FDA approved it in February 2023 (Glaxosmithkline Intellectual Property No LLC Ltd England). Its FDA protection (new chemical entity) runs to February 2028. Its 6 listed patents run to March 2038.
The first generic of Jesduvroq is expected in December 2033.
Why that month: patent 8,324,208, on the active ingredient and the product’s formulation, ends then. That is about 4.5 years before the last listed patent runs out, in March 2038.
Why a Generic Can Come Before March 2038
The last listed patent runs to March 2038; a court ruling or a settlement can bring a generic sooner. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Jesduvroq Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Jesduvroq’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 8,324,208, which ends in December 2028; the first generic is expected after it, in December 2033, about 7 years away. Why the later ones may not hold it back
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,557,834 | A way of using it (U-1238) | June 2027 | Active |
| 8,815,884 | The product’s formulation; a way of using it (U-1238) | June 2027 | Active |
| 11,643,397 | The active ingredient; a way of using it (U-3535) | June 2027 | Active |
| 8,324,208 Sets the expected month of generic availability | The active ingredient; the product’s formulation | December 2028 | Active |
| 11,117,871 | The active ingredient; the product’s formulation; a way of using it (U-3535) | March 2038 | Active |
| 11,649,217 | The product’s formulation; a way of using it (U-3535) | March 2038 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New chemical entity NCE | Five years of protection for a medicine whose active ingredient the FDA had never approved before. | February 2028 | Active |
Source: FDA Orange Book, application 216951. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Daprodustat
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Jesduvroq yet.
Approved by the FDA
Not yet. The FDA has not approved a generic daprodustat. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic daprodustat for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Jesduvroq Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Jesduvroq, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
Jesduvroq Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 1MG | Tablet | Oral | February 2023 | Discontinued reference product |
| 2MG | Tablet | Oral | February 2023 | Discontinued reference product |
| 4MG | Tablet | Oral | February 2023 | Discontinued reference product |
| 6MG | Tablet | Oral | February 2023 | Discontinued reference product |
| 8MG | Tablet | Oral | February 2023 | Discontinued reference product |
Source: FDA Orange Book, Glaxosmithkline Intellectual Property No LLC Ltd England. Listed for sale today by GlaxoSmithKline LLC (FDA NDC Directory).
Jesduvroq NDC Codes and Packages
Each Jesduvroq package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 00173-0897-13 | DAPRODUSTAT 1 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
| 00173-0897-13 | DAPRODUSTAT 1 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
| 00173-0903-13 | DAPRODUSTAT 2 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
| 00173-0903-13 | DAPRODUSTAT 2 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
| 00173-0906-13 | DAPRODUSTAT 4 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
| 00173-0906-13 | DAPRODUSTAT 4 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
| 00173-0911-13 | DAPRODUSTAT 6 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
| 00173-0911-13 | DAPRODUSTAT 6 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
| 00173-0914-13 | DAPRODUSTAT 8 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
| 00173-0914-13 | DAPRODUSTAT 8 mg/1 tablet, film coated | bottle of 30 tablets | GlaxoSmithKline LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Jesduvroq’s own FDA approval (NDA 216951) are listed, never a generic. Some codes belong to companies that repackage Jesduvroq: it is the same medicine in a different package.
What a Generic Jesduvroq Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Jesduvroq as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Jesduvroq”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Jesduvroq
Is there a generic for Jesduvroq right now?
No. As of October 9, 2026 no generic daprodustat is listed for sale in the FDA NDC Directory.
When will Jesduvroq go generic?
December 2033 is the expected month. It is when Jesduvroq’s patent 8,324,208 ends. That patent covers the active ingredient and the product’s formulation, and once it ends, generics should be able to go on sale as soon as the FDA approves them. The last listed patent runs to March 2038; a court ruling or a settlement can bring a generic sooner.
Will generic daprodustat be the same as Jesduvroq?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Jesduvroq?
Not yet. The FDA Orange Book lists no approved generic version of Jesduvroq.
When does the Jesduvroq patent expire?
The FDA Orange Book lists 6 patents for Jesduvroq; the last runs to March 2038. The one behind the expected month is patent 8,324,208, which ends in December 2028. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (December 2033) weighs all of that.
Changes to This Projection
- First generic expected December 2033 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- MekinistTrametinib Dimethyl Sulfoxide2027 to 2028
- ZolinzaVorinostatMarch 2028
- QuzyttirCetirizine HydrochlorideFebruary 2030
- GocovriAmantadine HydrochlorideMarch 2030
- CinvantiAprepitantJune 2032
- TukysaTucatinibApril 2034
About Jesduvroq
- Generic name daprodustat
- How it is taken By mouth
- Company Glaxosmithkline Intellectual Property No LLC Ltd England
- More drugs Brand-name drugs starting with J
- Have a question? A pharmacist answers, free. Ask about Jesduvroq
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.